GlassScriptPhysician profile
Nicholas Aberle
NPI 1659578060
$1,382.97
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $617 · 2021: $80.46 · 2022: $138 · 2023: $131 · 2024: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Surgical Group, LLC | $616.83 | 2020 | |
| Smith+Nephew, INC. | $154.27 | 2024 | Aetos Shoulder System, Bioinductive Implant With Arthroscopic Delivery System - Medium |
| Stryker Corporation | $114.67 | 2022-2024 | Axsos, Gamma |
| Medacta USA, INC. | $80.13 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $60.63 | 2022-2023 | Seglentis |
| Pacira Pharmaceuticals Incorporated | $41.20 | 2022-2023 | Iovera, Zilretta, Exparel |
| Bioventus LLC | $39.46 | 2023-2024 | Exogen Ultrasound Bone Healing System, Durolane |
| Integra Lifesciences Corporation | $34.50 | 2023 | Tenoglide |
| Encore Medical, LP | $33.81 | 2024 | Djo Surgical |
| Organogenesis INC. | $30.80 | 2021 | |
| Polynovo North America LLC | $24.07 | 2022 | |
| Zimmer Biomet Holdings, INC. | $22.19 | 2024 | Tapestry, Genex |
| Optinose US, INC. | $22.03 | 2021 | |
| Heron Therapeutics, INC. | $18.76 | 2024 | Zynrelef |
| Kaleo, INC. | $16.41 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.16 | 2024 | Bridion |
| Glaxosmithkline, LLC. | $15.42 | 2021 | |
| Melinta Therapeutics, LLC | $14.98 | 2024 | Kimyrsa |
| Depuy Synthes Sales INC. | $14.44 | 2022 | |
| Abbvie INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Aberle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.